Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Harenberg, Job [VerfasserIn]   i
 Krämer, Roland [VerfasserIn]   i
 Giese, Christina [VerfasserIn]   i
 Hetjens, Svetlana [VerfasserIn]   i
 Weiß, Christel [VerfasserIn]   i
 Wehling, Martin [VerfasserIn]   i
Titel:Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays
Titelzusatz:reduction of interassay variability
Verf.angabe:Job Harenberg, Roland Krämer, Christina Giese, Svetlana Marx, Christel Weiss, Martin Wehling
E-Jahr:2011
Jahr:3 August 2011
Umfang:5 S.
Fussnoten:Gesehen am 03.08.2022
Titel Quelle:Enthalten in: Journal of thrombosis and thrombolysis
Ort Quelle:Dordrecht [u.a.] : Springer Science + Business Media B.V, 1994
Jahr Quelle:2011
Band/Heft Quelle:32(2011), 3, Seite 267-271
ISSN Quelle:1573-742X
Abstract:Rivaroxaban and other oral direct factor Xa inhibitors (ODiXa) are currently developed for prophylaxis and treatment of thromboembolic diseases using fixed doses. Although routine monitoring is not required, assessing the intensity of anticoagulation may be useful under certain clinical conditions. ODiXa prolong coagulation times of several clotting assays and, thus, their concentration may be determined in factor Xa specific chromogenic substrate assays. So far, no standardized and validated assay is commercially available. Here, five methods (A through E) are studied and optimized to reduce interassay variability. Human pooled plasma was spiked by a serial dilution of rivaroxaban (25-900 ng/ml). The release of para-nitroaniline from the chromogenic substrates was measured by the optical density (OD) at 405 nm. Method B was identified to yield the lowest sum of deviations from the mean value of the OD concentration curve calculated from all assays. Spline functions were developed for OD versus concentration curves for all methods. The calculated OD versus concentration curves overlapped for all methods. The coefficient of variation for all assays and concentrations of rivaroxaban decreased from 25.3 ± 11.4% using the original data to 3.8 ± 2.2% using the calculated data (P < 0.0001). The robustness of the chromogenic assay (method B) remains to be corroborated in interlaboratory comparisons.
DOI:doi:10.1007/s11239-011-0622-5
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

kostenfrei: Volltext: https://doi.org/10.1007/s11239-011-0622-5
 kostenfrei: Volltext: https://link.springer.com/article/10.1007/s11239-011-0622-5
 DOI: https://doi.org/10.1007/s11239-011-0622-5
Datenträger:Online-Ressource
Sprache:eng
K10plus-PPN:1813078610
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68949834   QR-Code
zum Seitenanfang